- Home
- RNXT vs ADVM Comparison
RNXT vs ADVM Comparison
Compare RNXT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- ADVM
- Stock Information
- Founded
- RNXT 2012
- ADVM 2006
- Country
- RNXT United States
- ADVM United States
- Employees
- RNXT N/A
- ADVM N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNXT Health Care
- ADVM Health Care
- Exchange
- RNXT Nasdaq
- ADVM Nasdaq
- Market Cap
- RNXT 44.6M
- ADVM 47.4M
- IPO Year
- RNXT 2021
- ADVM 2014
- Fundamental
- Price
- RNXT $1.36
- ADVM $2.25
- Analyst Decision
- RNXT Strong Buy
- ADVM Strong Buy
- Analyst Count
- RNXT 2
- ADVM 5
- Target Price
- RNXT $7.25
- ADVM $26.40
- AVG Volume (30 Days)
- RNXT 190.7K
- ADVM 186.4K
- Earning Date
- RNXT 08-12-2025
- ADVM 08-11-2025
- Dividend Yield
- RNXT N/A
- ADVM N/A
- EPS Growth
- RNXT N/A
- ADVM N/A
- EPS
- RNXT N/A
- ADVM N/A
- Revenue
- RNXT $240,000.00
- ADVM $1,000,000.00
- Revenue This Year
- RNXT $3,186.05
- ADVM N/A
- Revenue Next Year
- RNXT $291.93
- ADVM $18.82
- P/E Ratio
- RNXT N/A
- ADVM N/A
- Revenue Growth
- RNXT N/A
- ADVM N/A
- 52 Week Low
- RNXT $0.75
- ADVM $1.78
- 52 Week High
- RNXT $1.69
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- RNXT 58.97
- ADVM 40.11
- Support Level
- RNXT $1.26
- ADVM $2.21
- Resistance Level
- RNXT $1.40
- ADVM $3.10
- Average True Range (ATR)
- RNXT 0.05
- ADVM 0.22
- MACD
- RNXT -0.01
- ADVM -0.00
- Stochastic Oscillator
- RNXT 48.70
- ADVM 4.49
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.